Clodronate treatment increases serum osteocalcin in normocalcemic osteolytic bone metastases.
28 consecutive patients with multiple osteolytic bone metastases due to various types of cancer were treated with 300 mg/day of sodium clodronate given intravenously as a 3-hour infusion, 16 patients were treated for 10 days and 12 for 20 days. Our findings showed that clodronate administration causes an increase in serum osteocalcin (sBGP) in the group of patients treated for 20 days (p less than 0.05), a reduction in serum Ca in both groups of patients (p less than 0.01), an increase in serum alkaline phosphatase (p less than 0.05 and p less than 0.01), a reduction in urinary Ca (p less than 0.01) and a reduction in uOHP (p less than 0.05). The raise in sBGP may be attributed to the reduction of sCa and to the consequent secondary hyperparathyroidism. The increase in sBGP can be considered as the expression of osteoblasts stimulation following an adequate period of therapy with sodium clodronate.
Conte
N
N
1. Divisione Medica, Ospedale Regionale di Treviso, Italia.
Di Virgilio
R
R
Da Rin
G
G
Roiter
I
I
Pavan
P
P
Legovini
P
P
Foscolo
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary*; D004002:Clodronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D010014:Osteolysis / Q000097:blood*; D010281:Parathyroid Hormone / Q000097:blood
D010281:Parathyroid Hormone; D004002:Clodronic Acid; D015675:Osteocalcin; D000469:Alkaline Phosphatase